Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells

Blood

Volumn 105, Issue 10, 2005, Pages 4013-4020

  Ramos, Adrian M ^a   Fernández, Carlos ^a   Amrán, Donna ^a   Sancho, Patricia ^a   De Blas, Elena ^a   Aller, Patricio ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; CAMPTOTHECIN; CASPASE 3; CISPLATIN; CYTOCHROME C; DNA; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN 27; LONIDAMINE; PEROXIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE B INHIBITOR AKT5; UNCLASSIFIED DRUG; WORTMANNIN;

APOPTOSIS; ARTICLE; ATTENUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; MEMBRANE DAMAGE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL TOXICITY; MYELOID LEUKEMIA; OXIDATION KINETICS; OXIDATIVE STRESS; PEROXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL;

EID: 18544374589     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2802     Document Type: Article

References (53)

1. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62:3893-3903.
2. Bode AM, Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hemat. 2002;42:5-24.
3. Miller WH Jr. Molecular targets of arsenic trioxide in malignant cells. Oncologist. 2002;7(suppl 1): 14-19.
4. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox systems. Blood. 1999;93:268-277.
5. Jing Y, Dai J, Chalmers-Redman REM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukaemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94:2102-2111.
6. Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer. 1999;81:796-799.
7. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood. 2001;98:805-813.
8. Dickinson DA, Forman HJ. Cellular glutathione andthiols metabolism. Biochem Pharmacol. 2002;64:1019-1026.
9. 2+-dependent production of Superoxide. Int J Cancer. 2001;92:518-526.
10. Scott N, Hatlelid KM, MacKenzie NE, Carter DE. Reactions of arsenic(III) and arsenic(V) species with glutathione. Chem Res Toxicol. 1993;6:102-106.
11. Lo JF, Wang HF, Tam MF, Lee TC. Glutathione S-transferase pi in an arsenic-resistant Chinese hamster ovary cell line. Biochem J. 1992;288:977-982.
12. Liu J, Chen H, Miller DS, et al. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol. 2001;60:302-309.
13. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res. 2000;256:34-41.
14. Wada T, Penniger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004;23:2838-2849.
15. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updates. 2002;5:234-248.
16. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene. 2003;22:8983-8998.
17. Dutcher JP. Mammalian target of rapamycin inhibition. Clin Cancer Res. 2004;10:6382S-6387S.
18. Sordet O, Rebe C, Leroy I, et al. Mitochondria-targeting drugs arsenic trioxide and Ionidamine bypass the resistance of TPA-dirferentiated leukemic cells to apoptosis. Blood. 2001;97:3931-3940.
19. Fernández C, Ramos AM, Sancho P, Amrán D, De Blas E, Alter P. 12-O-tetradecanoylphorbol-13-acetate may both potentiate and decrease the generation of apoptosis by the antileukemic agent arsenic trioxide in human promonocytic cells: regulation by extracellular signal-regulated protein kinases and glutathione. J Biol Chem. 2004;279:3877-3884.
20. Li S, Li X, Roznaski, GJ. Regulation of glutathione in cardiac myocytes. J Mol Cell Cardiol. 2003;35:1145-1152.
21. Kim SK, Woodcroft KJ, Khodadadeh SS, Novak RF. Insulin signaling regulates gamma-glutamyl-cysteine ligase catalytic subunit expression in primary cultured rat hepatocytes. J Pharmacol Exp Ther. 2004;311:99-108.
22. Sundström C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int J Cancer. 1976;17:565-577.
23. Collins S, Gallo R, Gallagher R. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977;270:347-349.
24. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi R, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukaemia (M3). Blood. 1991;77:1080-1086.
25. Renvoize C, Roger R, Moulian N, Bertoglio J, Bréard J. Bcl-2 expression in target cells leads to functional inhibition of caspase-3 protease family in human NK and lymphokine-activated killer cell granule-mediated apoptosis. J Immunol. 1997;159:126-134.
26. Troyano A, Sancho P, Fernández C, De Blas E, Bernardi P, Aller P. The selection between apoptosis and necrosis is differentially regulated in hydrogen peroxide-treated and glutahione-depleted human promonocytic cells. Cell Death Differ. 2003;10:889-898.
27. Bellosillo B, Villamor N, López-Guillermo A, et al. Spontaneous and drug-induced apoptosis mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukaemia. Blood. 2002;100:1810-1816.
28. LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2′,7′, dichlorofluorescein as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol. 1992;5:227-231.
29. Troyano A, Fernánez C, Sancho P, De Blas E, Aller P. Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells: the role of intracellular oxidation. J Biol Chem. 2001;276:47107-47115.
30. Fariss MW, Reed DJ. High-performance liquid chromatography of thiols and disulfides: dinitrophenol derivatives. Methods Enzymol. 1987;143:101-109.
31. Lee TC, Wei ML, Chang WJ, et al. Elevation of glutathione levels and glutathione S-transferase activity in arsenic-resistant Chinese hamster ovary cells. In Vitro Cell Dev Biol. 1989;25:442-448.
32. Galán A, García-Bermejo ML, Troyano A, et al. Stimulation of p38 mitogen-activated protein kinase is an early regulatory event for the cadmium-induced apoptosis in human promonocytic cells. J Biol Chem. 2000;275:11418-11424.
33. Hu Y, Qiao L, Wang S, et al. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem. 2000;43:3045-3051.
34. Ravagnan L, Marzo I, Constantini P, et al. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene. 1999;18:2537-2546.
35. Plo I, Bettaïeb A, Payrastre B, et al. The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukaemia cell lines. FEBS Lett. 1999;425:150-154.
36. Choi YJ, Park JW, Suh SI, et al. Arsenic trioxide-induced apptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. Int J Oncol. 2002;21:603-610.
37. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science. 1999;286:1741-1744.
38. Kim A, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis-signal regulating kinase 1. Mol Cell Biol. 2001;21:893-901.
39. Park HS, Kim MS, Huh SH, et al. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem. 2002;277:2573-2578.
40. Larochette N, Decaudin D, Jacotot E, et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res. 1999;249:413-421.
41. Adrain C, Martin SJ. The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. Trends Biochem Sci. 2001;26:390-397.
42. Slee EA, Keogh SA, Martin SJ. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ. 2000;7:556-565.
43. Takayama S, Reed JC, Homma, S. Heat-shock proteins as regulators of apoptosis. Oncogene. 2003;22:9041-9047.
44. Liu H, Perlman H, Pagliari LJ, Pope RM. Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages: role of Mcl-1, independent of nuclear factor (NF)-κB, Bad, or caspase activation. J Exp Med. 2001;194:113-126.
45. Xu Q, Simpson SE, Scialla TJ, Bagg A, Caroll M. Survival of acute myeloid leukaemia cells requires PI3 kinase activation. Blood. 2003;102:972-980.
46. O'Groman DM, McKenna SL, McGahon AJ, Knox KA, Cotter TG. Sensitation of HL60 human leukemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia. 2000;14:602-611.
47. Martelli AM, Tazzari PL, Tabellini G, et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans retinoic acid, and ionizing radiation of human leukaemia cells. Leukemia. 2003;17:1794-1805.
48. Sugimoto K, Toyoshima H, Sakai R, et al. Frequent mutations in the p53 gene in human myeloid leukaemia cell lines. Blood. 79:2378-2383.
49. Nimbalkar D, Henry MK, Quelle FW. Cytokine activation of phosphoinosite 3-kinase sensitizes hematopoietic cells to cisplatin-induced death. Cancer Res. 2003;63:1034-1039.
50. Mak NK, Wong RN, Leung KN, Fung M. Involvement of tumor necrosis factor (TNF-α) in arsenic trioxide induced apoptotic cell death of murine myeloid leukemia cells. Toxicol Lett. 2002;135:79-87.
51. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood. 2003;101:4078-4087.
52. Sun WM, Huang ZZ, Lu SC. Regulation of gamma-glutamylcysteine synthetase by protein phosphorylation. Biochem J. 1996;320(pt 1):321-328.
53. Yi J, Gao F, Shi G, et al. The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis. 2002;7:209-215.